“Buoyed by the robust growth of global biopharma, we set up our R&D service pipeline in the United
States with the aim of developing our platform in two core markets. This way, Genetron can not
only synchronize its services but also establish industry benchmarks, facilitating future
Sino-U.S. dual market approvals.”
In 2020, Dr. Yunfu Hu (former Deputy Director of the FDA Center for Medical Devices and Radiological
Health (CDRH)/Office of In-Vitro Diagnostic and Radiological Health (OIR)) joined Genetron Health as
its CMO. During his FDA tenure, Dr. Hu oversaw the approval process for a number of the world’s
first companion diagnostic products.
Genetron’s comprehensive platform features innovative patented technologies such as ”One-Step
Method“ and a nationwide marketing network, enabling our veteran registry team to provide clients
with integrated companion diagnostic product R&D and commercialization services.
Accounting for the full biopharma
Genetron’s one-stop solution ranges from clinical trial design consultations to patient
recruitment, and from biomarker testing services (CAP & CLIA dual-certified laboratory quality
control) to subsequent data mining.
Genetron’s big data platform
helps enable precision
testing for early stage research and targeted screening solutions for the users of biopharma
partners. Our team provides industry-leading expertise and support for new drug development and